Yifeng Pharmacy vs Laobaixing Pharmacy: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Yifeng Pharmacy (603939.CG)

Q3 202624 Jul – 27 Aug 2026

▲4

Yifeng buybacks, dividend and steady H1 profit growth lift the stock

Company starts buying back its own shares Yifeng said it will spend 200-300 million yuan buying back its own stock at up to 30.56 yuan a share, to fund employee incentives. By early August it had already bought 1.78 million shares for 39.62 million yuan. Buybacks shrink the shares outstanding and signal management thinks the stock is cheap.
The buyback is the main new capital action supporting the price this period.
First-half profit grew faster than sales First-half revenue rose 3.5% to 12.13 billion yuan and net profit rose about 9.5% to 964 million yuan, helped by cost cuts. The company kept opening stores, ending with 15,239 outlets. Profit growing faster than sales shows the core pharmacy business is still healthy.
The interim results are the fundamental driver behind the stock's move.
Cash dividend announced alongside results Yifeng plans to pay 0.3 yuan per share in cash, about 363 million yuan, or 37.6% of first-half profit. A payout of that size returns real cash to shareholders and supports the shares, though it also means less money kept inside the company for expansion.
The dividend is a new shareholder-return event that supports the price.
Buyback wave shows industry capital returning Yifeng's buyback is part of a broad wave of Shanghai-listed companies buying back stock and insiders raising stakes, with 190 new buyback plans worth up to 55.5 billion yuan this year. This broad flow of company money into the market lifts sentiment for names like Yifeng.
It explains the wider market backdrop that amplifies Yifeng's own buyback.

August 202624 Jul – 27 Aug 2026

▲4

Yifeng buybacks, dividend and steady H1 profit growth lift the stock

Company starts buying back its own shares Yifeng said it will spend 200-300 million yuan buying back its own stock at up to 30.56 yuan a share, to fund employee incentives. By early August it had already bought 1.78 million shares for 39.62 million yuan. Buybacks shrink the shares outstanding and signal management thinks the stock is cheap.
The buyback is the main new capital action supporting the price this period.
First-half profit grew faster than sales First-half revenue rose 3.5% to 12.13 billion yuan and net profit rose about 9.5% to 964 million yuan, helped by cost cuts. The company kept opening stores, ending with 15,239 outlets. Profit growing faster than sales shows the core pharmacy business is still healthy.
The interim results are the fundamental driver behind the stock's move.
Cash dividend announced alongside results Yifeng plans to pay 0.3 yuan per share in cash, about 363 million yuan, or 37.6% of first-half profit. A payout of that size returns real cash to shareholders and supports the shares, though it also means less money kept inside the company for expansion.
The dividend is a new shareholder-return event that supports the price.
Buyback wave shows industry capital returning Yifeng's buyback is part of a broad wave of Shanghai-listed companies buying back stock and insiders raising stakes, with 190 new buyback plans worth up to 55.5 billion yuan this year. This broad flow of company money into the market lifts sentiment for names like Yifeng.
It explains the wider market backdrop that amplifies Yifeng's own buyback.

Latest24 Jul – 27 Aug 2026

▲4

Yifeng buybacks, dividend and steady H1 profit growth lift the stock

Company starts buying back its own shares Yifeng said it will spend 200-300 million yuan buying back its own stock at up to 30.56 yuan a share, to fund employee incentives. By early August it had already bought 1.78 million shares for 39.62 million yuan. Buybacks shrink the shares outstanding and signal management thinks the stock is cheap.
The buyback is the main new capital action supporting the price this period.
First-half profit grew faster than sales First-half revenue rose 3.5% to 12.13 billion yuan and net profit rose about 9.5% to 964 million yuan, helped by cost cuts. The company kept opening stores, ending with 15,239 outlets. Profit growing faster than sales shows the core pharmacy business is still healthy.
The interim results are the fundamental driver behind the stock's move.
Cash dividend announced alongside results Yifeng plans to pay 0.3 yuan per share in cash, about 363 million yuan, or 37.6% of first-half profit. A payout of that size returns real cash to shareholders and supports the shares, though it also means less money kept inside the company for expansion.
The dividend is a new shareholder-return event that supports the price.
Buyback wave shows industry capital returning Yifeng's buyback is part of a broad wave of Shanghai-listed companies buying back stock and insiders raising stakes, with 190 new buyback plans worth up to 55.5 billion yuan this year. This broad flow of company money into the market lifts sentiment for names like Yifeng.
It explains the wider market backdrop that amplifies Yifeng's own buyback.

Laobaixing Pharmacy (603883.CG)

Q3 202624 Jul – 9 Oct 2026

▲3

Laobaixing pushes buybacks, incentives, and new business bets

Buyback and dual incentive plan signal confidence Laobaixing launched a 40–80 million yuan share buyback plus restricted stock and employee ownership plans for over 340 people, with net profit targets of at least 75% growth in 2027 and 100% in 2028. This aligns management with shareholders and supports the stock price.
This is the biggest new event, directly boosting investor confidence and the share price.
Buyback already executed, returning cash to shareholders By September 30, 2026, Laobaixing had repurchased 3.24 million shares for 41.62 million yuan at 12.55–13.03 yuan per share. This shows the buyback is actually happening, which can support the share price by reducing shares outstanding.
It confirms the earlier buyback plan is being carried out, a concrete positive for the stock.
New pharmacy-plus venture and internet hospital expand business Laobaixing will invest 5.1 million yuan for 51% of a new company to explore a pharmacy-plus format, and it fully owns a new internet hospital in Chengdu. These small bets aim to create new growth beyond traditional drugstores.
These are new business initiatives that could drive future growth, a positive for the stock.
Interim profit steady but cash flow and margins weaken First-half 2026 revenue was 10.998 billion yuan and net profit 447 million yuan, but operating cash flow fell 13.66% and gross margin slipped. The profit is a positive, yet weaker cash and margins are a real counterweight for investors.
It gives the fundamental backdrop and a fair counterweight to the positive news.

August 202624 Jul – 9 Oct 2026

▲3

Laobaixing pushes buybacks, incentives, and new business bets

Buyback and dual incentive plan signal confidence Laobaixing launched a 40–80 million yuan share buyback plus restricted stock and employee ownership plans for over 340 people, with net profit targets of at least 75% growth in 2027 and 100% in 2028. This aligns management with shareholders and supports the stock price.
This is the biggest new event, directly boosting investor confidence and the share price.
Buyback already executed, returning cash to shareholders By September 30, 2026, Laobaixing had repurchased 3.24 million shares for 41.62 million yuan at 12.55–13.03 yuan per share. This shows the buyback is actually happening, which can support the share price by reducing shares outstanding.
It confirms the earlier buyback plan is being carried out, a concrete positive for the stock.
New pharmacy-plus venture and internet hospital expand business Laobaixing will invest 5.1 million yuan for 51% of a new company to explore a pharmacy-plus format, and it fully owns a new internet hospital in Chengdu. These small bets aim to create new growth beyond traditional drugstores.
These are new business initiatives that could drive future growth, a positive for the stock.
Interim profit steady but cash flow and margins weaken First-half 2026 revenue was 10.998 billion yuan and net profit 447 million yuan, but operating cash flow fell 13.66% and gross margin slipped. The profit is a positive, yet weaker cash and margins are a real counterweight for investors.
It gives the fundamental backdrop and a fair counterweight to the positive news.

Latest24 Jul – 9 Oct 2026

▲3

Laobaixing pushes buybacks, incentives, and new business bets

Buyback and dual incentive plan signal confidence Laobaixing launched a 40–80 million yuan share buyback plus restricted stock and employee ownership plans for over 340 people, with net profit targets of at least 75% growth in 2027 and 100% in 2028. This aligns management with shareholders and supports the stock price.
This is the biggest new event, directly boosting investor confidence and the share price.
Buyback already executed, returning cash to shareholders By September 30, 2026, Laobaixing had repurchased 3.24 million shares for 41.62 million yuan at 12.55–13.03 yuan per share. This shows the buyback is actually happening, which can support the share price by reducing shares outstanding.
It confirms the earlier buyback plan is being carried out, a concrete positive for the stock.
New pharmacy-plus venture and internet hospital expand business Laobaixing will invest 5.1 million yuan for 51% of a new company to explore a pharmacy-plus format, and it fully owns a new internet hospital in Chengdu. These small bets aim to create new growth beyond traditional drugstores.
These are new business initiatives that could drive future growth, a positive for the stock.
Interim profit steady but cash flow and margins weaken First-half 2026 revenue was 10.998 billion yuan and net profit 447 million yuan, but operating cash flow fell 13.66% and gross margin slipped. The profit is a positive, yet weaker cash and margins are a real counterweight for investors.
It gives the fundamental backdrop and a fair counterweight to the positive news.